WebApr 5, 2024 · Company Description. Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and … WebApr 5, 2024 · The company reported a net loss of $88 million, or $6.16 per share, for the year ended December 31, 2024, compared to a net loss of $34.5 million, or $2.33 per share in 2024. The net loss for the ...
Eledon Pharmaceuticals, Inc. (ELDN) Stock Price Today, Quote & News …
WebMar 30, 2024 · Eledon Pharmaceuticals, Inc. informó de los resultados de ganancias para el año completo finalizado el 31 de diciembre de 2024. Para el año completo, la empresa informó de una pérdida neta de 87,97 millones de USD, frente a los 34,51 millones de USD de hace un año. WebMar 30, 2024 · Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development … cooper 16178
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year …
WebInvestors. Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people … WebApr 13, 2024 · Eledon Pharmaceuticals Inc (ELDN) stock is down -7.38% while the S&P 500 is higher by 1.21% as of 2:09 PM on Thursday, Apr 13. ELDN is down -$0.18 from … WebApr 10, 2024 · ELDN Complete Eledon Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. co open houses